Multiple Myeloma
Multiple Myeloma is a cancer that forms in a type of white blood cell called plasma cells, which help produce antibodies. This condition can lead to bone damage, kidney problems, and a weakened immune system.
Multiple Myeloma: Etentamig and Iberdomide Study
We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have a confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM)?
- Have you received treatment with etentamig before?
- Have you had any prior treatment with BCMA-targeted therapy?
- Have you taken any cereblon E3 ligase modulatory drugs like iberdomide or mezigdomide?
- Is your performance status rated as 0 or 1 on the ECOG scale (meaning you are fully active or restricted in physically strenuous activity only)?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
AbbV-383
Iberdomide
Human IgG4 Monoclonal Antibody Against BCMA and CD3
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Davunfite
Imnovid
Polidma
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Regional Universitaire De Tours
Service Hématologie et Thérapie Cellulaire
La Riche, France
Centre Hospitalier Universitaire De Lille
Service des maladies du sang
Loos, France
Centre Hospitalier Regional De Marseille
Service d'hématologie
Marseille, France
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.